A Closer Look at the Dermatological Profile of GLP-1 Agonists
Background/objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in treating type 2 diabetes and obesity, offering established metabolic and cardiovascular benefits. Emerging evidence suggests these agents also exert direct dermatologic effects. This systematic review cate...
Saved in:
| Main Authors: | Calista Persson, Allison Eaton, Harvey N. Mayrovitz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Diseases |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-9721/13/5/127 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study
by: Lauren M. Ching, BS, et al.
Published: (2025-10-01) -
Secukinumab: In psoriasis and beyond
by: Aditya K. Bubna, et al.
Published: (2025-01-01) -
Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
by: Saurabh Bhatia
Published: (2022-09-01) -
Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
by: Saurabh Bhatia
Published: (2022-09-01) -
The Impact of Surgery on Quality of Life in Hidradenitis Suppurativa: Results from a Prospective Single-Center Study
by: Lennart Ocker, et al.
Published: (2025-05-01)